论文部分内容阅读
目的探讨恩替卡韦治疗慢性重症乙型病毒性肝炎患者的临床效果。方法选取2014年1月至2015年12月在大连市第六人民医院接受治疗的60例慢性重症乙型病毒性肝炎患者作为研究对象,按随机数字表法将其分为对照组与观察组,各30例。对照组患者给予常规对症治疗,观察组患者在对照组基础上采用恩替卡韦进行治疗,比较两组患者肝功能、乙肝病毒DNA(HBV-DNA)水平、临床治疗效果及不良反应发生情况。结果治疗后,两组患者的血浆ALB、ALT、AST、TB-K及PT均明显低于治疗前,且观察组患者的TB-K水平显著低于对照组,差异均有统计学意义(均P<0.05),但两组患者的血浆ALB、ALT、AST及PT差异均无统计学意义(均P>0.05);治疗后,观察组患者的HBV-DNA水平显著低于对照组,差异有统计学意义(P<0.05)。结论恩替卡韦能有效抑制慢性重症乙型病毒性肝炎患者的病毒复制,改善肝功能水平,且安全性较高。
Objective To investigate the clinical efficacy of entecavir in the treatment of chronic severe hepatitis B patients. Methods Sixty patients with chronic severe hepatitis B who were treated in the Sixth People’s Hospital of Dalian City from January 2014 to December 2015 were selected as research subjects and divided into control group and observation group according to random number table method. 30 cases each. Patients in the control group were treated with conventional symptomatic treatment. The patients in the observation group were treated with entecavir on the basis of the control group. The liver function, HBV-DNA level, clinical efficacy and adverse reactions of the two groups were compared. Results After treatment, the plasma levels of ALB, ALT, AST, TB-K and PT in the two groups were significantly lower than those before treatment, and the TB-K levels in the observation group were significantly lower than those in the control group P <0.05). However, there were no significant differences in plasma ALB, ALT, AST and PT between the two groups (all P> 0.05). After treatment, HBV-DNA levels in the observation group were significantly lower than those in the control group Statistical significance (P <0.05). Conclusion Entecavir can effectively inhibit viral replication in patients with chronic severe hepatitis B, improve liver function and have higher safety.